Coenzyme Q<sub>10</sub> as an Inhibitor of Effector Release from One-Electron-Reduced Bioreductive Anticancer Prodrugs.

However, some single-agent activity for tarloxotinib against the HER2 cohort in a subsequent trial has been seen [ 19 ], and evofosfamide combined with gemcitabine in a Phase III pancreatic cancer trial narrowly failed to reach significance [ 20 ].

also in 4,113 other papers